Another paper suggested discontinuation of SGLT-2 inhibitors in patients with diabetes and COVID-19 and avoidance of adding SGLT-2 inhibitors in anti-diabetic therapy for all patients with diabetes during the COVID-19 pandemic due to increased expression of ACE-2 enzyme, which could be an entry point for SARS-CoV-234. The gene discussed is SLC5A2; the disease is COVID-19.